Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features

Leukemia

Volumn 21, Issue 1, 2007, Pages 79-83

  Breccia, M ^a   Avvisati, G ^b   Latagliata, R ^a   Carmosino, I ^a   Guarini, A ^a   De Propris, M S ^a   Gentilini, F ^a   Petti, M C ^c   Cimino, G ^a   Mandelli, F ^a   Lo Coco, F ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; BREAST CANCER RESISTANCE PROTEIN 1; BREAST CANCER RESISTANCE PROTEIN 3; CD15 ANTIGEN; CD2 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD9 ANTIGEN; FLT3 LIGAND; IDARUBICIN; RETINOIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; FEMALE; HEART VENTRICLE THROMBOSIS; HUMAN; IMMUNOPHENOTYPING; ISCHEMIC HEART DISEASE; LEUKEMIA CELL; LEUKOCYTE COUNT; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; RETINOIC ACID SYNDROME; RISK ASSESSMENT; SEX RATIO; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOPHILIA; THROMBOSIS;

EID: 33845519881     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404377     Document Type: Article

References (38)

1. Sanz MA, Jarque I, Martin G. Acute promyelocytic leukaemia therapy: results and prognostic factors. Cancer 1988; 1: 7-13.
2. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukaemia. Blood 1992; 79: 543-553.
3. Dombret H, Scrobohaci ML, Ghorra P, Zini JM, Daniel MT, Castaigne S et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia 1993; 7: 2-9.
4. Barbui T, Finazzi G, Falanga A. The impact of all-trans retinoic acid on the coagulopathy of acute promyelocytic leukaemia. Blood 1998; 91: 3093-3102.
5. Runde V, Aul C, Heyll A, Schneider W. All-trans retinoic acid: Not only a differentiating agent but also an inducer of thromboembolic events in patients with M3 leukemia. Blood 1992; 79: 534-535.
6. Tallman MS, Lefebvre P, Baine RM, Shoji M, Cohen I, Green D et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukaemia. J Thromb Haemostasis 2004; 2: 1341-1350.
7. Runde V, Aul C, Sudhoff T, Heyll A, Schneider W. Retinoic acid in the treatment of acute promyelocytic leukemia: Inefficacy of the 13-cis isomer and induction of complete remission by the all-trans isomer complicated by thromboembolic events. Ann Hematol 1992; 64: 270-272.
8. de Lacerda JF, do Carmo JA, Guerra ML, Geraldes J, de Lacerda JM. Multiple thrombosis in acute promyelocytic leukaemia after tretinoin. Lancet 1993; 342: 114-115.
9. Hashimoto S, Koike T, Tatewaki W, Seki Y, Sato N, Azegami T et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 1994; 8: 1113-1115.
10. Escudier SM, Kantarjian HM, Estey EH. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma 1996; 20: 435-439.
11. Goldschmidt N, Gural A, Ben Yehuda D. Extensive splenic infarction, deep vein thrombosis and pulmonary emboli complicating induction therapy with all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia. Leuk Lymphoma 2003; 44: 1433-1437.
12. De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L et al. The risk of thrombosis in patients with acute leukemia: Occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemostasis 2005; 3: 1985-1992.
13. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014-1021.
14. Diverio D, Riccioni R, Pistilli A, Buffolino S, Avvisati G, Mandelli F et al. Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia. Leukemia 1996; 10: 1214-1216.
15. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Ann Biochem 1987; 162: 156-159.
16. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
17. Noguera NI, Breccia M, Divona M, Diverio D, Costa V, De Santis S et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002; 16: 2185-2189.
18. Avvisati G, ten Cate JW, Buller JW, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukemia. Lancet 1989; 2: 122-124.
19. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
20. Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425.
21. Seya T, Tejima H, Fukuda H, Hara T, Matsumoto M, Hatanaba M et al. Acute promyelocytic leukaemia with CD59 deficiency. Leuk Res 1993; 17: 895-896.
22. Claxton DF, Reading CL, Nagarajan L, Tsujimoto Y, Andersson BS, Estey E et al. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukaemia. Blood 1992; 80: 582-586.
23. Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantu-Rajnolidi A et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: Correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol 1998; 102: 1035-1041.
24. Albano F, Mestice A, Pannunzio A, Lanza F, Martino B, Pastore D et al. The biological characteristics of CD34+CD2+ adult acute promyelocytic leukemia and the CD34-CD2- hypergranular and microgranular phenotypes. Haematologica 2006; 91: 311-316.
25. Di Noto R, Schiavone EM, Ferrara F, Manzo C, Lo Pardo C, Del Vecchio L. Expression and ATRA-driven modulation of adhesion molecules in acute promyelocytic leukemia. Leukemia 1994; 8: 1900-1905.
26. Thomas X, Anglaret B, Campos L, Thiebaut A, Sabido O, Bailly M et al. Expression of beta1-integrins and pseudo-immunoglobulins on acute promyelocytic leukaemia cells and its modifications during in vitro differentiation. Leuk Res 1998; 22: 61-68.
27. Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16: 369-385.
28. Di Noto R, Lo Pardo C, Schiavone EM, Ferrara F, Manzo C, Vacca C et al. All-trans retinoic acid and the regulation of adhesion molecules in acute myeloid leukemia. Leuk Lymphoma 1996; 21: 201-209.
29. Noguera N, Breccia M, Divona M, Diverio D, Costa V, De Santis S et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002; 16: 2185-21889.
30. Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF et al. NCRI Adult Leukemia Working Party. Blood 2005; 106: 3768-3776.
31. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukaemia. Blood 2002; 100: 132-1542.
32. Marasca R, Maffei R, Zucchini P, Castelli I, Saviola A, Martinelli S et al. Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with FLT3 mutational status. Leukemia 2006; 20: 103-114
33. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Shepherd L et al. All trans retinoic acid in acute promyelocytic leukaemia. N Engl J Med 1997; 337: 1021-1028.
34. Di Bona E, Avvisati G, Castaman G, Vegna ML, De Sanctis V, Rodeghiero F et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Hematol 2000; 108: 689-695.
35. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Clinical results. Blood 1990; 76: 1704-1709.
36. Fenaux P, Castaigne S, Dombret H. All trans retinoic acid as first line therapy of acute promyelocytic leukaemia. A report on 31 cases. Br J Haematol 1991; 77 (Suppl 1): (abs 126), p 44.
37. Tsukada N, Wada K, Aoki S, Hashimoto S, Kishi K, Takahashi M et al. Induction therapy with all-trans retinoic acid for acute promyelocytic leukaemia: A clinical study of 10 cases, including a fatal case with thromboembolism. Intern Med 1996; 35: 10-14.
38. Pogliani EM, Rossini F, Casaroli I, Maffe P, Corneo G. Thrombotic complications in acute promyelocytic leukemia during all-trans retinoic acid therapy. Acta Haematol 1997; 97: 228-230.